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Abstract
Cannabinoids can activate CB1 and CB2 receptors. Since a CB2 mRNA has been described in rat peritoneal mast cells
(RPMC), we investigated a series of cannabinoids and derivatives for their capacity to stimulate RPMC. Effects of natural
cannabinoids v9-tetrahydrocannabinol (v9-THC), v8-THC, endocannabinoids (anandamide, palmitoylethanolamide) and
related compounds (N-decanoyl-, N-lauroyl-, N-myristoyl-, N-stearoyl- and N-oleoyl-ethanolamines; N-palmitoyl
derivatives (-butylamine, -cyclohexylamine, -isopropylamine) ; and N-palmitoyl, O-palmitoylethanolamine), and synthetic
cannabinoids including WIN 55,212-2, SR141716A and SR144528 were assessed for their capacity to induce histamine
release or prime RPMC stimulated by compound 48/80. Only v9-THC and v8-THC could induce non-lytic, energy- and
concentration-dependent histamine releases from RPMC (respective EC50 values: 23.5 þ 1.2; 53.4 þ 20.6 WM, and maxima:
71.2 þ 5.5; 55.7 þ 2.7% of the total RPMC histamine content). These were not blocked by CB1 (SR141716A) or CB2
(SR144528) antagonists, but reduced by pertussis toxin (100 ng/ml). Endocannabinoids and analogues did neither induce
histamine secretion, nor prime secretion induced by compound 48/80 (0.2 Wg/ml). v9-THC and v8-THC induced in vitro
histamine secretion from RPMC through CB receptor-independent interactions, partly involving Gi=o protein
activation. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mast cells and basophils are polyfunctional im-
mune cells implicated in immediate hypersensitivity
and the initiation and development of the in£amma-
tory reaction. These cells are present in many tissues
and their activation results in the release of potent
preformed and newly formed mediators, such as his-
tamine, proteases, cytokines or metabolites of arachi-
donic acid. The direct consequence of this activation
is tissue swelling and/or damage, modi¢cation of
function, leucocyte invasion and pain. Abnormal reg-
ulation of mast cell physiology leading to cell secre-
tion may represent a pathophysiological situation
leading to chronic in£ammation and ultimately to a
loss of tissue and/or organ function [1].
Natural cannabinoids, originally extracted from
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the leaves of Cannabis sativa, were used for over 4000
years both for their medicinal and psychomimetic
e¡ects. v9-Tetrahydrocannabinol (v9-THC) was the
¢rst active isolated cannabinoid, or marihuana-de-
rived molecule, and was described as highly psycho-
active [2]. Recently discovered and cloned receptors
[3^5] for cannabinoids have speeded up the under-
standing of their underlying molecular mechanisms.
The two subtypes of these G protein coupled recep-
tors are the CB1, very abundant in the brain areas
and supposed to mediate neurobehavioural e¡ects,
and the CB2, restricted to date on cells of the im-
mune system, and thought to modulate immunolog-
ical responses.
A potential endogenous lipidic ligand was ¢rst dis-
covered in porcine brain [6] and shown to have func-
tional e¡ects in vitro or in vivo in the rat brain [7,8].
This molecule, N-arachidonoylethanolamine or
anandamide, was also shown to have functional ac-
tivity in mouse vas deferens [6] and its presence was
noticed in peripheral tissues of rat and human beings
[9]. The central/peripheral classi¢cation may there-
fore be too elementary. Another endogenous com-
pound, N-palmitoylethanolamine (PEA), ¢rst de-
scribed to be present in the rat brain, liver and
muscle [10], was reported to be a potent nanomolar
agonist for the CB2 receptor [11] and to display anti-
in£ammatory e¡ects [12,13]. The absence of binding
of this compound to brain membranes suggested a
high selectivity for peripheral CB2 receptor [14,15].
However, several authors failed to ¢nd any PEA
binding to CB2 receptors ([16] for review). PEA, as
other N-acylated glycerophospholipids, has been
shown to accumulate in in£ammatory tissues [17].
It reduces tissue in£ammation in vivo [18], down-
modulates mast cell activation in vivo [19] and in
contrast to anandamide, inhibits immunogenic acti-
vation in RBL-2H3 cells [11]. The capacity of these
plant-derived or endogenous molecules to modify
mast cell histamine release in vitro is currently un-
known. To address this question, we assessed for this
function cannabinoids from natural (v9- and v8-
THC), endogenous (anandamide and PEA) and syn-
thetic (palmitoylethanolamide analogues, WIN
55,212-2, SR141716A and SR144528) origin. Consid-
ering the di¡erent pathways of activation of rat peri-
toneal mast cells (RPMC) and the existence of a
modulation by PEA of the immunological one [11],
we focused our interest on the e¡ect of these various
cannabinoids on the secretion occurring through the
alternate, receptor-independent pathway of mast cell
stimulation [20^22].
2. Materials and methods
2.1. Chemistry
N-Acylethanolamines including PEA (Table 1,
compounds 1^10) were prepared as described else-
where [23], from their respective acyl chlorides and
amines. Spectroscopic data (1H- and 13C-nuclear
magnetic resonance, IR) and elemental analysis
were in accordance with their chemical structures.
2.2. Chemicals
v9-THC, v8-THC, benzalkonium chloride (BAC, a
mixture of quaternary benzyldimethylalkylammo-
nium chlorides), pertussis toxin (PTX), dinitrophenol
(DNP), 2-deoxy-D-glucose (deoxyGlc), compound
48/80 and bovine serum albumin (BSA) were bought
from Sigma-Aldrich (St. Louis, MO, USA) and
anandamide from Cayman Chemical (Ann Arbor,
MI, USA). The synthetic agonist WIN 55,212-2
was from RBI (Natick, MA, USA) or from NEN
(Boston, MA, USA) when tritiated, and the CB1
antagonists SR141716A and SR144528 were a gen-
erous gift from Sano¢ Recherche (Montpellier,
France). All other chemicals were of analytical grade
and purchased from Sigma-Aldrich or from Merck
Eurolab (Louvain, Belgium).
2.3. Mast cells
The procedure followed in the care and euthanasia
of the animals was in accordance with the European
Community standards on the care and use of labo-
ratory animals (Europe Directive 86/609/CEE Nov.
24, 86). RPMC were puri¢ed from male albino Wis-
tar rats weighing 300^350 g. The rats were sacri¢ced
by stunning and bleeding. Then, 10 ml of physiolog-
ical salt solution (PSS) containing (mM): NaCl, 137;
KCl, 2.7; CaCl2, 0.3; MgCl2, 1; NaH2PO4, 0.4; glu-
cose, 5.6; HEPES [4-(2-hydroxyethyl)-1-piperazine-
ethanesulphonic acid], 10 and NaOH to pH 7.4, sup-
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plemented with 0.2% BSA, were injected intraperito-
neally. The peritoneal cavity was opened after a 2 min
gentle massage and the peritoneal £uid collected and
centrifuged for 2 min at 180Ug. Mast cells were
puri¢ed from the resuspended pellet by centrifuga-
tion for 10 min at 220Ug on a BSA gradient (40
and 30%, w/v).
2.4. [3H]WIN 55,212-2 binding to mast cells
Binding studies with [3H]WIN 55,212-2 (5^100
nM) were conducted in intact cells at 4‡C in Hanks’
balanced salt solution with fatty acid-free BSA in
Maxisorp 96-well plates (Nunc, Roskilde, Denmark).
To de¢ne non-speci¢c binding, 10 WM unlabelled
WIN 55,212-2 was present when required. Com-
pounds were added with the tritiated ligand, and cells
(5U105) were then pipetted into the well. After
30 min, cell suspension was rapidly ¢ltered on GF/
C glass ¢bre ¢lters (Whatman, Maidstone, UK) us-
ing a 12-well Brandel cell harvester. Radioactivity on
¢lters was measured with a Beckman L-counter by
liquid scintillation in Aquasol-2 (New England Nu-
clear, Boston, MA, USA).
2.5. Histamine release from mast cells
After a 5 min equilibration period of the mast cells
(15 000^20 000 puri¢ed mast cells/assay) at 37‡C in
PSS, the cells were challenged for 5 min with the
various compounds. The reactions were stopped by
adding ice cold bu¡er to the samples. Histamine
from supernatants was assayed £uorometrically ac-
cording to the method of Shore et al. [24] without
extraction steps, and expressed as a percentage of the
total histamine content of the cells, determined by
lysing control cells with trichloroacetic acid. Sponta-
neous histamine release never exceeded 8% and was
subtracted from the induced releases.
2.6. Inhibition of histamine release
Treatment of the mast cells with 5.6 mM 2-deoxy-
D-glucose (instead of 5.6 mM glucose, control) and/
or 100 WM dinitrophenol was done in PSS for 30 min
at 37‡C. The e¡ect of pertussis toxin on histamine
release was assessed after incubation of the mast cells
for 2 h at 37‡C in PSS. After either of these treat-
ments, the cells were challenged for 5 min with the
various cannabinoids as described above.
The e¡ect of BAC, a mixture of quaternary ben-
zyldimethylalkylammonium chlorides, on histamine
release was assayed as described previously [25], al-
lowing BAC and the cannabinoids to act simultane-
ously for 10 min at 37‡C on puri¢ed mast cells in
PSS.
2.7. Statistics
Values are means þ S.E.M. of the indicated num-
ber of duplicate experiments. Statistical analyses of
data were established using the two-tail Student’s
t-test (*P6 0.05, signi¢cantly di¡erent from control).
3. Results
3.1. E¡ects of natural and synthetic cannabinoids on
histamine release from mast cells
Natural cannabinoids v9-THC or v8-THC, endog-
enous molecules anandamide or PEA, PEA deriva-
tives (Table 1, compounds 1^10) and synthetic mol-
ecules like SR141716A, SR144528 (CB1 and CB2
Fig. 1. E¡ect of various cannabinoid derivatives on histamine
release from mast cells. Puri¢ed rat peritoneal mast cells in bal-
anced salt solution supplemented with 0.2% BSA were stimu-
lated for 5 min at 37‡C with the indicated molecules. All the
PEA derivatives induced no histamine release; their results are
summarized within the open circle symbol. Values are means
þ S.E.M. of three duplicate experiments. S.E.M. not shown are
included within the symbols.
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antagonists, respectively) or WIN 55,212-2 were as-
sayed as triggers for histamine release from rat peri-
toneal mast cells. Fig. 1 shows that only v9-THC and
v8-THC were able to induce a concentration-depen-
dent histamine release, with EC50 values of 23.5 þ 1.2
and 53.4 þ 20.6 WM, reaching a maximum of
71.2 þ 5.5 and 55.7 þ 2.7% of the total histamine con-
tent of the cells, respectively. Anandamide had no
e¡ect on histamine release until 3U1034 M (Fig. 1).
3.2. Metabolic dependence of cannabinoid-induced
histamine release
Due to the high cannabinoid concentrations
needed to induce histamine liberation, experiments
were carried out with 2-deoxy-D-glucose (non-hydro-
lysable glucose substitute) and/or DNP (mitochon-
drial respiration chain blocker) to assess the func-
tionality of the histamine secretion from mast cells
and to verify that histamine was not released through
membrane destruction. Inhibition of the histamine
release induced by v9-THC and v8-THC was partial
by substituting glucose by 2-deoxy-D-glucose, but to-
tal when combined with DNP (Fig. 2), showing the
energy dependence, i.e. the physiological process of
the mechanism. However, 2-deoxy-D-glucose and/or
DNP did not inhibit the histamine release induced by
the endogenous cannabinoid anandamide (Fig. 2),
suggesting a non-physiological, possibly deleterious
e¡ect on mast cell membranes.
3.3. Receptor-independent e¡ects of cannabinoids in
rat mast cells
The CB antagonists SR141716A and SR144528,
assayed up to 10 WM on histamine secretion induced
by v9-THC (Fig. 3A) and v8-THC (Fig. 3B), only
showed signi¢cant inhibitory e¡ects when used at the
highest concentration and for only one concentration
(3U1035 M) of both cannabinoids.
PTX was able to inhibit histamine secretion by up
to 75% in the case of v8-THC (Fig. 4), the histamine
Fig. 2. Inhibition by 2-deoxy-D-glucose and/or dinitrophenol of
histamine release induced by v9-THC, v8-THC and anandamide
from mast cells. Puri¢ed rat peritoneal mast cells were treated
in balanced salt solution supplemented with 0.2% BSA for
30 min at 37‡C with 2-deoxy-D-glucose (deoxyGlc, 5.6 mM)
and/or dinitrophenol (DNP, 100 WM) before being stimulated
for 5 min with v9-THC, v8-THC and anandamide at the indi-
cated concentrations. Results are expressed as percentage of in-
hibition of the corresponding controls (i.e., histamine release in
the absence of deoxyGlc and DNP, and in the presence of
5.6 mM glucose). These control values were 79.7 þ 5.7% of the
total histamine content for v9-THC, 55.7 þ 2.7% for v8-THC
and 50.7 þ 6.2% for anandamide. Values are means þ S.E.M. of
three duplicate experiments. S.E.M. not shown are included
within the bars.
Table 1
Homologues (1^6) and analogues (7^10) of N-palmitoylethanol-
amine
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releaser compound 48/80 being used as internal con-
trol. On the other hand, up to its subtoxic concen-
trations, BAC, supposed to interact with G-proteins,
showed no e¡ect on histamine secretion induced by
the natural cannabinoids (Fig. 5). All PEA deriva-
tives were also assayed as potential primers for the
histamine secretion induced by compound 48/80 to
highlight a possible modulatory e¡ect (Table 2). For
all the derivatives and concentrations tested, only N-
palmitoylcyclohexylamine (8) showed a signi¢cant in-
hibition (P6 0.05), at 1034 M, of the histamine se-
cretion induced by compound 48/80.
3.4. [3H]WIN 55,212-2 binding to mast cells
In our experimental conditions with intact RPMC,
no speci¢c binding of [3H]WIN 55,212-2 (5^100 nM),
Fig. 3. E¡ect of SR141716A and SR144528 on mast cell histamine secretion induced by (A) v9-THC and (B) v8-THC. Puri¢ed rat
peritoneal mast cells were treated with the CB receptor antagonists for 10 min at 37‡C at the indicated concentrations in balanced
salt solution supplemented with 0.2% BSA, before being stimulated for 5 min with various concentrations of v9- and v8-THC. Values
are means þ S.E.M. of three duplicate experiments. S.E.M. not shown are included within the bars. *Signi¢cantly di¡erent from con-
trol stimulation, in the absence of antagonist with the corresponding concentration of v9- or v8-THC (P6 0.05).
6
Fig. 4. Inhibition by pertussis toxin of mast cell histamine se-
cretion induced by v9-THC, v8-THC and compound 48/80. Pu-
ri¢ed rat peritoneal mast cells were treated with 10 or 100 ng/
ml of pertussis toxin for 2 h at 37‡C in balanced salt solution
supplemented with 0.2% BSA before being stimulated for 5 min
with the indicated concentrations of v9-THC, v8-THC and
compound 48/80. Results are expressed as percentage of inhibi-
tion of the corresponding controls (i.e., histamine secretion in
the absence of pertussis toxin). These control values were
81.9 þ 3.8% of the total histamine content for v9-THC,
64.7 þ 4.8% for v8-THC and 37.2 þ 2.0% for compound 48/80.
Values are means þ S.E.M. of three duplicate experiments.
S.E.M. not shown are included within the bars.
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a radioligand known to bind to both cannabinoid
receptors with a preference for CB2, was observed.
4. Discussion
Mast cells are polyfunctional immune cells impli-
cated in allergy and in the development of in£amma-
tion. As a CB2 mRNA has been described in mast
cells [11], they may represent a potential target for
cannabinoids. Cannabinoid receptors recognized a
diversity of chemical structures. In this investigation
of the e¡ects of cannabinoids to induce or modulate
histamine release from rat peritoneal mast cells, we
include di¡erent cannabinoids di¡ering by their
source (natural, endogenous, synthetic) and by their
function (agonists, antagonists). We show that rat
peritoneal mast cells are able to secrete histamine
when stimulated by v9- and v8-THC, two well-
known potent natural cannabinoids [26]. This e¡ect
is not shared by other cannabinoids used in this
study, whatever their function on the receptors:
both agonists (WIN 55,212-2) and antagonists
(SR141716A and SR144528) as well as analogues
of palmitoylethanolamide have no e¡ect on hista-
mine release. The only exception was anandamide.
However, this could only be observed at a high con-
centration, which proved to be deleterious to mast
cells, as energy deprivation did not lower anand-
amide-induced histamine release. Obviously, the abil-
ity to modulate histamine secretion strictly depends
on the chemical structure: only the cannabinoids
containing the benzopyran ring exhibited these prop-
erties.
PEA has been reported to be highly e¡ective in
reducing antigen-evoked [3H]serotonin release from
RPMC [11]. It can moderate mast cell activation
Fig. 5. E¡ect of benzalkonium chloride on mast cell histamine
release induced by v9-THC, v8-THC and compound 48/80. Pu-
ri¢ed rat peritoneal mast cells were triggered for 10 min at
37‡C in balanced salt solution supplemented with 0.2% BSA by
a mixture of various concentrations of benzalkonium chloride
and 1034 M v9-THC, 1034 M v8-THC or 0.2 Wg/ml compound
48/80. Values are means þ S.E.M. of three duplicate experi-
ments. S.E.M. not shown are included within the bars. *Signi¢-
cantly di¡erent from control stimulation, without BAC
(P6 0.05).
Table 2
E¡ect on mast cell histamine secretion by compound 48/80 of a pretreatment with non-stimulating concentrations of PEA and its de-
rivatives
48/80 (0.2 Wg/ml) preceded by treatment with [PEA derivatives] log(M)
36 35 34
1 50.0 þ 7.0 50.3 þ 8.1 40.2 þ 6.5
2 51.4 þ 8.3 49.1 þ 5.3 45.7 þ 9.1
3 52.6 þ 6.5 49.9 þ 7.7 36.7 þ 6.4
PEA 58.5 þ 2.1 57.0 þ 1.0 52.3 þ 1.9
5 52.0 þ 6.0 49.5 þ 8.5 40.9 þ 7.7
6 53.2 þ 7.0 47.3 þ 7.5 48.0 þ 5.2
7 52.4 þ 6.7 50.7 þ 10.6 43.1 þ 7.5
8 52.0 þ 6.8 49.3 þ 6.6 31.9 þ 8.0*
9 51.4 þ 5.3 52.7 þ 8.5 45.0 þ 5.0
10 52.9 þ 5.8 51.6 þ 6.6 39.2 þ 8.1
48/80 (0.2 Wg/ml) alone 54.8 þ 6.0
Rat peritoneal mast cells were treated or not with PEA and its various derivatives for 10 min at 37‡C at the indicated concentrations
in PSS before being stimulated for 5 min with 0.2 Wg/ml of compound 48/80. Values are histamine secretions (% of total), expressed
as means þ S.E.M. of three duplicate experiments. *Signi¢cantly di¡erent from stimulation by compound 48/80 alone (P6 0.05).
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induced in vivo by substance P, which would point
towards a local autacoid anti-in£ammatory function
[19]. Substance P triggers rat peritoneal mast cells
through a non-immunological transductional path-
way, often referred to as peptidergic pathway and
common to amphiphilic positively charged molecules
(e.g. compound 48/80 or mastoparan [20,21,27,28]).
We hence tried to highlight an in vitro modulation
by cannabinoids of compound 48/80-stimulated mast
cells. Of the various derivatives of PEA, assayed as
primers on RPMC in vitro, only N-palmitoylcyclo-
hexylamine (8) modi¢ed histamine secretion induced
by compound 48/80. As such, the downmodulating
e¡ect of PEA, which has been reported in vivo, may
result from a combination of cellular, immunological
and/or biochemical signals, and not only from its
e¡ects on mast cells.
A dominating peripheral localization for the CB2
receptor subtype has been proposed, particularly in
studies on immune cells [5,29], and the presence of
CB2 mRNA has previously been noticed in rat peri-
toneal mast cells [11]. However, we did not observe
CB2 receptors in RPMC with [3H]WIN 55,212-2, a
preferential CB2 ligand [30]. Also, SR144528, a CB2
antagonist [31], did not reduce histamine release in-
duced by v9- or v8-THC. As these are known to be
active on both CB1 and CB2 receptors, we used the
CB1 antagonist SR141716A [32] to evidence a possi-
ble CB1 receptor-mediated subtype on mast cells.
SR141716A did not reduce histamine release induced
by v9- or v8-THC, suggesting that no CB1 receptors
are involved in this mechanism. Therefore, our re-
sults do not support the hypothesis of the presence
of functional CB1 or CB2 receptors in rat peritoneal
mast cells in our experimental conditions.
PTX-sensitive Gi and Go proteins have been found
in RPMC [20,22,28,33] and are implicated in the pep-
tidergic receptor-independent stimulation pathway.
Benzalkonium chloride, a germicide shown to be a
selective inhibitor of histamine release induced by
compound 48/80 [25] and supposed to act at the G-
protein level, revealed no signi¢cant concentration-
dependent inhibitory e¡ect on histamine release in-
duced by v9-THC or v8-THC. However, PTX parti-
ally reduced histamine secretion induced by v9- and
v8-THC, indicating that Gi=o proteins were only
partly responsible for this phenomenon. CB1 and
CB2 receptors have been shown to couple to PTX-
sensitive G-proteins [34,35], but our results in RPMC
do not support a classical ligand-receptor interaction.
Instead, we wish to propose that v9- and v8-THC are
capable of inducing histamine release by using, only
to a certain extent, the peptidergic Gi=o-related secre-
tion pathway.
Natural cannabinoids may exert immunosuppres-
sive e¡ects, at high concentrations, by inhibiting the
B lymphocyte proliferation [36,37]. This e¡ect was
not blocked by pertussis toxin pretreatment, indicat-
ing the involvement of cannabinoid-induced mem-
brane e¡ects on lymphocytes [38] in addition to their
low nanomolar immunostimulant receptor-mediated
e¡ects [38]. Cannabinoids can indeed a¡ect enzymes
or ion channels [39^43]. Membrane structure seems
to be modi¢ed by cannabinoids: they can position
themselves within or near the membrane [44,45], or
change lipid order [46] and di¡usion [47^49]. Some
e¡ects were also found not to be correlated with
pharmacological potency [46].
Considering (i) the particularity of RPMC, which
can secrete histamine following the classical immuno-
logical or the peptidergic receptor-independent acti-
vation, and (ii) the highly hydrophobic structure of
v9-THC, v8-THC, PEA and the other cannabinoids
described above, it may be assumed that all the ef-
fects observed in these cells may result from CB re-
ceptor-independent interactions. These interactions,
deleterious in the case of anandamide, remain phys-
iological even at high concentrations for the two ac-
tive molecules, the plant-derived v9-THC and v8-
THC. Moreover, they partly involve Gi=o protein ac-
tivation.
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